(Q51313042)

3 April 2018

title

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. (English)

1 reference

3 April 2018

1 reference

1 reference

8

Susan O'Brien

1 reference

3 April 2018

9

John C Byrd

1 reference

3 April 2018

10

Ranjana Advani

1 reference

3 April 2018

Juthamas Sukbuntherng

2

object named as

Juthamas Sukbuntherng

1 reference

3 April 2018

David J Loury

3

object named as

David Loury

1 reference

3 April 2018

author name string

Eleonora Marostica

1

1 reference

3 April 2018

Jan de Jong

4

1 reference

3 April 2018

Xavier Woot de Trixhe

5

1 reference

3 April 2018

An Vermeulen

6

1 reference

3 April 2018

Giuseppe De Nicolao

7

1 reference

3 April 2018

Jesse McGreivy

11

1 reference

3 April 2018

Italo Poggesi

12

1 reference

3 April 2018

publication date

8 November 2014

1 reference

3 April 2018

Cancer Chemotherapy and Pharmacology

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

3 April 2018

volume

75

1 reference

3 April 2018

issue

1

1 reference

3 April 2018

page(s)

111-121

1 reference

3 April 2018

https://scigraph.springernature.com/pub.10.1007/s00280-014-2617-3

exact match

0 references

cites work

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Estimating data transformations in nonlinear mixed effects models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

The effect of collinearity on parameter estimates in nonlinear mixed effect models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

Mechanism-based concepts of size and maturity in pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2617-3

10.1007/S00280-014-2617-3

21 January 2018

Identifiers

DOI

1 reference

3 April 2018

1 reference

3 April 2018